BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Cash Flow Reinvestment Rate
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow Reinvestment Rate of 0.29x as of June 2024, reinvesting €2.43 Billion (capex €2.23 Billion plus investments €-200.00 Million) from operating cash flow of €8.36 Billion. See BEXIMCO PHARMA.GDR REGS 1 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BEXIMCO PHARMA.GDR REGS 1 Cash Flow Reinvestment Rate (2022–2024)
Historical reinvestment intensity for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. For the full cash flow conversion analysis, see cash flow conversion of BEXIMCO PHARMA.GDR REGS 1.
Annual Cash Flow Reinvestment Rate for BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Year-by-year capital reinvestment analysis for BEXIMCO PHARMA.GDR REGS 1. See BEXIMCO PHARMA.GDR REGS 1 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.29x | €2.43 Billion | €8.36 Billion | €2.23 Billion | ▼ -34.6% |
| 2023 | 0.45x | €2.71 Billion | €6.08 Billion | €2.71 Billion | ▼ -21.0% |
| 2022 | 0.56x | €2.94 Billion | €5.21 Billion | €2.94 Billion | — |